The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock decreased 3.55% or $1.39 during the last trading session, reaching $37.79. About 233,849 shares traded or 93.67% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 29, 2018 and is uptrending. It has outperformed by 35.02% the S&P500.
The move comes after 9 months negative chart setup for the $981.20 million company. It was reported on Mar, 29 by Barchart.com. We have $36.28 PT which if reached, will make NASDAQ:IFRX worth $39.25 million less.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual earnings per share reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 41.94 % negative EPS growth.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Seekingalpha.com which released: “InflaRx: Buy The Dip – Seeking Alpha” on June 29, 2018, also Globenewswire.com with their article: “InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing – GlobeNewswire” published on October 30, 2018, Globenewswire.com published: “InflaRx Opens New Research Facility in Ann Arbor – GlobeNewswire” on June 05, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors – GlobeNewswire” published on September 21, 2018 as well as Globenewswire.com‘s news article titled: “InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” with publication date: November 08, 2018.
– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $981.20 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.